We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for avelumab (Merck Healthcare Pty Ltd)
Active ingredients
avelumab
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy
Therapeutic area
Oncology